INTELLIA THERAPEU DL-,01 WKN: A2AG6H ISIN: US45826J1051 Kürzel: NTLA Forum: Aktien Thema: Hauptdiskussion

Intellia Therapeutics Enters Lease Agreement to Build Manufacturing Facility for its CRISPR-based Therapies https://www.globenewswire.com/news-release/2022/02/23/2390327/0/en/Intellia-Therapeutics-Enters-Lease-Agreement-to-Build-Manufacturing-Facility-for-its-CRISPR-based-Therapies.html • State-of-the-art GMP manufacturing facility to support preclinical through commercial production of Intellia’s investigational therapies • New facility in Waltham, Massachusetts expected to be operational in 2024

Intellia and ONK Therapeutics Announce Collaboration to Advance Allogeneic CRISPR-Edited NK Cell Therapies for the Treatment of Patients with Cancer https://finance.yahoo.com/news/intellia-onk-therapeutics-announce-collaboration-123000355.html

Intellia Therapeutics Announces Acquisition of Rewrite Therapeutics https://www.globenewswire.com/news-release/2022/02/03/2378394/0/en/Intellia-Therapeutics-Announces-Acquisition-of-Rewrite-Therapeutics.html

So langsam wird's wieder interessant. Ein Boden erkennt man nicht...

https://www.nasdaq.com/articles/intellias-ntla-crispr-therapies-show-promise-amid-competition Intellia's (NTLA) CRISPR Therapies Show Promise Amid Competition

Ja, das Problem mit der Bewertung findet sich nicht nur hier und deshalb hatte ich nach der Durchbruchsmeldung auch meinen Bestand teils reduziert. Investiert bin ich weiterhin, aber von gerechtfertigt lässt sich natürlich nicht unbedingt sprechen 🙃. Eher davon, dass die Zukunft gehandelt wird.

Summer76, Du scheinst der Firma im Derail zu folgen. Ich überlege einnen Einstieg, finde aber die Bewertung ziemlich astronomisch. Ist sie gerexhtfertigt im Vergleich zu anderen Crispr-cas9 companies ?

Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM) https://www.globenewswire.com/news-release/2021/11/22/2338871/0/en/Intellia-Therapeutics-Announces-Expansion-of-Ongoing-Phase-1-Study-of-NTLA-2001-to-Include-Adults-with-Transthyretin-Amyloidosis-with-Cardiomyopathy-ATTR-CM.html Approved protocol amendment enables enrollment of ATTR-CM patients in the ongoing first-in-human study of NTLA-2001, a systemically delivered CRISPR/Cas9-based therapy

Intellia accelerates plans to evaluate ATTR amyloidosis candidate in cardiomyopathy Nov. 04, 2021 7:59 AM ETIntellia Therapeutics, Inc. (NTLA)By: Jonathan M Block, SA News Editor  Meletios Verras/iStock via Getty Images Intellia Therapeutics (NASDAQ:NTLA) has decided to accelerate plans to evaluate NTLA-2001, its candidate for ATTR amyloidosis, in patients with cardiomyopathy. The company said that based on an interim dataset, it is seeking regulatory feedback on inclusion of cardiomyopathy patients in its current phase 1 study. Intellia is eyeing presenting interim data from part 1, a single-ascending dose portion, and to begin part 2, a single-cohort expansion, in Q1 2022. Elsewhere in the pipeline, the company is planning to begin enrollment in a phase 1 study of NTLA-2002 for hereditary angioedema by the end of the year. Also, by 1H 2022, Intellia's plans to nominate its first allogeneic development candidate. In Q3 2021, Intellia's net loss widened ~158% to $71.6M (0.97 per share basic and diluted) due to a significant decline in collaboration revenue and an increase in R&D expenses

Ist natürlich noch nicht wirklich relevant

Intellia Therapeutics EPS misses by $0.11, misses on revenue Nov. 04, 2021 7:32 AM ETIntellia Therapeutics, Inc. (NTLA)By: Gaurav Batavia, SA News Editor Intellia Therapeutics (NASDAQ:NTLA): Q3 GAAP EPS of -$0.97 misses by $0.11. Revenue of $7.21M (-67.5% Y/Y) misses by $1.45M. Press Release Cash, cash equivalents and marketable securities were $1,148.7 million as of September 30, 2021, compared to $597.4 million as of December 31, 2020. The increase was driven by net proceeds of $648.3 million from a follow-on offering in Q3 2021, $45.3 million of net proceeds from the Company’s “At the Market” agreement, $40.8 million in proceeds from employee-based stock plans, and $4.2 million of funding for a cost-sharing agreement received from Regeneron. These increases were offset in part by cash used to fund operations of approximately $187.3 million.

Etwas ausführlicher: Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis https://www.globenewswire.com/news-release/2021/10/21/2318228/0/en/Intellia-Therapeutics-Receives-U-S-FDA-Orphan-Drug-Designation-for-NTLA-2001-an-Investigational-CRISPR-Therapy-for-the-Treatment-of-Transthyretin-ATTR-Amyloidosis.html

Intellia granted Orphan Drug designation for transthyretin amyloidosis program https://newsfilter.io/a/a34daaacd54413360e2cadfaf0fcfc76 • The FDA has granted Orphan Drug designation to Intellia Therapeutics' (NTLA +0.3%) NTLA-2001 treatment for transthyretin amyloidosis ("ATTR"). • The gene editing therapy use a knockout edit to reduce circulating TTR protein levels. • Intellia is partnered with Regeneron Pharmaceuticals (REGN +0.9%) on NTLA-2001. • NTLA-2001 was granted Orphan Drug designation by the European Commission in March.

Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its Broad Genome Editing Capabilities at the 2021 European Society of Gene & Cell Therapy Annual Congress https://www.globenewswire.com/news-release/2021/10/20/2317270/0/en/Intellia-Therapeutics-Presents-Preclinical-Data-Demonstrating-Advancements-in-its-Broad-Genome-Editing-Capabilities-at-the-2021-European-Society-of-Gene-Cell-Therapy-Annual-Congres.html • First preclinical data demonstrating Intellia’s allogeneic platform creates immune-evading T cells for therapeutic use in future cancer treatments • Demonstrated lipid nanoparticle-based delivery as a more efficient multiplex gene editing approach for engineered cell therapies as compared to electroporation • Achieved durable production of normal human alpha-1 antitrypsin protein levels and reduction of endogenous disease-associated protein in non-human primates for the treatment of liver and/or lung manifestations of alpha-1 antitrypsin deficiency (AATD) • Platform advances support acceleration of future drug development candidates from both Intellia’s in vivo and ex vivo research portfolio ...

Kommt dieses Jahr eigentlich noch was an Ergebnissen?🤔

Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology https://www.globenewswire.com/news-release/2021/10/13/2313317/0/en/Intellia-Therapeutics-and-SparingVision-Announce-Strategic-Collaboration-to-Develop-Novel-Ocular-Therapies-Using-CRISPR-Cas9-Technology.html • Collaboration combines Intellia’s proprietary genome editing technology platform with SparingVision’s significant ophthalmology expertise • Intellia will grant SparingVision exclusive rights to its leading in vivo CRISPR/Cas9 technology for the development of ocular therapies directed to three targets • Intellia will receive an equity stake in SparingVision and will have an option to obtain exclusive US commercialization rights for ocular therapies for two targets ...